Yoshino Susumu, Tagawa Takashi, Awa Riyo, Ogasawara Jun, Kuwahara Hiroshige, Fukuhara Ikuo
Research Center, Maruzen Pharmaceuticals, Co., Ltd, Hiroshima 729-3102, Japan.
Fukuhara Clinic, Hokkaido 061-1351, Japan.
Food Funct. 2021 Mar 1;12(4):1603-1613. doi: 10.1039/d0fo01217c.
Visceral fat is a more important factor in obesity-associated disorders in Japanese individuals than in Caucasian individuals. The objective of this randomised, double-blind, placebo-controlled parallel group study, conducted in Japanese overweight adults, was to investigate the effects of polymethoxyflavone purified from Kaempferia parviflora on visceral fat. A total of 80 subjects (aged 20-64 years, 23.0 ≤ body mass index < 30 kg m-2) were randomly assigned in 1 : 1 ratio to either the active (polymethoxyflavone purified from K. parviflora) or placebo group. Over a 12-week period, each subject received two capsules containing polymethoxyflavone purified from K. parviflora (12 mg polymethoxyflavone per day) or placebo. The primary outcome was a reduction in visceral fat area (VFA), while the secondary outcome was a reduction in subcutaneous fat area (SFA) and total fat area (TFA). VFA was measured at 0, 8, and 12 weeks using computed tomography scanning. Results showed that VFA significantly reduced after 12 weeks in the active group and was significantly lower than in the placebo group at 8 and 12 weeks. A significant reduction was observed in SFA and TFA after 8 and 12 weeks in the active group; TFA was significantly lower than that in the placebo group at 8 and 12 weeks. No adverse events associated with the test supplements were observed in either group. Our study shows that administration of polymethoxyflavone purified from K. parviflora reduces visceral fat in Japanese overweight adults.
与白种人相比，内脏脂肪在日本肥胖相关疾病中是一个更重要的因素。这项在日本超重成年人中进行的随机、双盲、安慰剂对照平行组研究的目的是调查从小花山柰中纯化的多甲氧基黄酮对内脏脂肪的影响。总共80名受试者（年龄在20 - 64岁之间，体重指数23.0≤体重指数<30 kg/m²）以1∶1的比例随机分配到活性组（从K. parviflora中纯化的多甲氧基黄酮）或安慰剂组。在12周的时间里，每个受试者每天接受两粒含有从K. parviflora中纯化的多甲氧基黄酮（12毫克多甲氧基黄酮）的胶囊或安慰剂。主要结局是内脏脂肪面积（VFA）的减少，次要结局是皮下脂肪面积（SFA）和总脂肪面积（TFA）的减少。使用计算机断层扫描在0、8和12周时测量VFA。结果显示，活性组在12周后VFA显著降低，并且在8周和12周时显著低于安慰剂组。活性组在8周和12周后SFA和TFA显著降低；在8周和12周时TFA显著低于安慰剂组。两组均未观察到与试验补充剂相关的不良事件。我们的研究表明，给予从K. parviflora中纯化的多甲氧基黄酮可减少日本超重成年人的内脏脂肪。
